CURE4 CYSTIC FIBROSIS

ALL FOR THE FIGHT

ANNUAL IMPACT REPORT 2017-18

CONTENTS

C4 CF

OUR BATTLE CRY

WE ARE JOINING FORCES WITH A FORMIDABLE COMMUNITY TO FUND A REACHABLE AND FULLY ACCESSIBLE CURE FOR CYSTIC FIBROSIS.

TOGETHER, AND ONLY TOGETHER, ARE WE ABLE TO TAKE THE ACTION NECESSARY TO PURSUE A FUTURE FREE OF THIS DISEASE.

OUR VALUES

IMPACTFUL

WE WANT TO GIVE CYSTIC FIBROSIS THE VISIBILITY AND RESOURCES IT NEEDS TO ACCELERATE A CURE.

COLLABORATIVE

WE FORM A DEEPER CONNECTION WITH OUR SUPPORTERS TO BUILD A RESILIENT COMMUNITY OF LIKE-MINDED GO-GETTERS, FOR WHOM WE ARE FOREVER GRATEFUL.

INTEGRITY

WE REMAIN UNCOMMONLY ACCOUNTABLE AND TRANSPARENT WHEN IT COMES TO OUR GOALS AND OPERATIONS.

INSPIRATIONAL

WE SPREAD THE POWER OF OPTIMISM WITH A RELENTLESSLY WARM SPIRIT.

PASSIONATE

OUR HEARTS, HEADS, TALENTS AND TIME ARE ALL FOR THE FIGHT.

FROM OUR CHAIRMAN

DAVID COLUCCIO, *CHAIRMAN, CURE4 CYSTIC FIBROSIS*

On behalf of the Board of Directors, I would like to thank the Cure4 Cystic Fibrosis Foundation (C4CF) community for another outstanding contribution in 2017/18. We continue to amass an army of passionate supporters across Australia, made up of more than 1,000 individuals and organisations, who proudly demonstrate that they are all for the fight.

Together, we raised more than $1M. This is a wonderful achievement that once again saw the C4CF deliver the greatest source of funding, outside of the Federal Government, in support of cystic fibrosis research and development.

The past 12 months has seen much change, bringing with it renewed clarity of purpose. We bid a fond farewell to our staff members, Linda Jones and Kerry Southwell, who achieved so much in placing C4CF at the forefront of the cystic fibrosis community right across Australia. We express our deep gratitude for the dedicated service they provided to our Foundation and the community. In turn, we have welcomed our new Executive Manager, Suzy Dimaline, Donor Development Manager, Jessica Buckley, and Marketing and Communications Manager, Jodi Farley. Responding to the growing needs of the organisation, this investment in staff provides C4CF with the organisational stability and critical skills to successfully move away from our dependence on grant income and establish a broad base of nationwide, community support.

In early 2017, the board established a new strategic direction which was based upon the four pillars of:

1. Community engagement and philanthropy;
2. Scientific research and commercialisation;
3. Research advocacy and influence; and
4. Governance.

With changes in our staff mix and with continued strong growth in our fundraising, the board took the opportunity to review our operations. Significantly, in line with our strategic pillars, we determined the need for a more expert and independent oversight of our grant administration process. The identified outcomes-oriented approach of the National Foundation for Medical Research and Innovation (NFMRI) combined with their promotion of industry collaboration, strongly aligned with our strategy and vision.

Commencing in 2018/19, C4CF will commence a three-year pilot partnership with NFRMI which will see us expand our grant program to the scientific research community across Australia. The broad reach of the NFMRI grant program to universities and medical research institutes nationwide means that C4CF can identify and fund the best CF research initiatives aimed at extending the life expectancy of people living with CF.

In partnership with the Fay Fuller Foundation, our continued support of the Cystic Fibrosis Airway Research Group based at the Allan Scott CF Research Laboratory in Adelaide, saw C4CF invest more than $780K in direct funding support for staff, purchases of critical equipment, funding for important national and international conferences, direct funding of a research administrator and funding of PhD scholarships for talented students interested in pursuing research into cystic fibrosis.

In its first year, the Fay Fuller Discovery Project has enabled the research team to uncover new ground and progress their study of the effectiveness of corrective gene therapy on the living lung of a CF rat.

In July, C4CF commenced an expert review of CFARG's research and development activities, as well as commercial pathways. This review will take place over several months, and ultimately provide assessments and recommendations on relevant commercial pathways for the respective technologies. We look forward to providing you with updates as this work progresses.

In June, we welcomed Gandel Philanthropy, one of the country's largest philanthropic organisations, to our community. Gandel Philanthropy's generous grant of $166K will fund the appointment of an X-Ray Lung Functioning Imaging Analyst based at Monash University and the Australian Synchrotron. This will enable mass data generated through research to be deciphered and we look forward to sharing the outcomes of this data in the next 12 months.

We received further generous gifts from the Hackett Foundation who have donated over $265,000 in the last two years in support of CF research.

I would also like to acknowledge the generous support of our major donors and all our contributors without whom we would not be able to advance Australian research to cure cystic fibrosis. We understand the demands upon your time and your purse and so we continue to be humbled by your ongoing, generous support of our organisation.

Finally, I wish to express my gratitude for the dedication and hard work of the C4CF Board and staff. The manner in which our talented team of people apply themselves to the task while also remaining so tightly focused on our strategy and mission is quite astounding and at the root of our continued growth.

This will be my last report to you as Chairman of C4CF Foundation. I have now completed the maximum three terms as a Director and will retire as Chairman in September.

It has been a privilege and an honour to serve the Board as its Chairman for the last eight years and an even bigger honour to serve the cystic fibrosis community as we continue to strive and fight to end this insidious disease. I am incredibly proud of the talent we have been able to assemble to further this goal in the form of my fellow directors and our dedicated staff. It is humbling to look back and see how much we have achieved and how far we have come.

While there is still much work to do, I could not wish for a more capable person than Jo Close to provide new drive and intelligent and highly competent leadership. The C4CF Board of Directors unanimously voted Jo as Chair and she will assume the role in September 2018. I look forward to seeing the Foundation prosper under Jo's leadership.

I will remain, as always, a committed and passionate fighter for a future free from cystic fibrosis.

"IT HAS BEEN A PRIVILEGE AND AN HONOUR TO SERVE THE BOARD AS ITS CHAIRMAN FOR THE LAST EIGHT YEARS AND AN EVEN BIGGER HONOUR TO SERVE THE CYSTIC FIBROSIS COMMUNITY."

IDENTICAL TWINS AUSTIN AND LEVI
CF WARRIORS

INTRODUCING JO CLOSE

CHAIR OF CURE4 CYSTIC FIBROSIS FOUNDATION

C4CF Foundation is proud to introduce Ms Jo Close as the new Chair of the Foundation.

Jo was appointed to the Cure4 Cystic Fibrosis Foundation Board in December 2013 and has been an active contributor to the development of the organisation's strategy. She is a passionate advocate for the development of a strong community support base, and a keen participant in many of our fundraising endeavours and activities.

Jo is a scientist with an accomplished career in research strategy and management. She has managed major research centres, institutes and programs within all three South Australian universities and undertook formative roles within the local bioscience industry and investment sector. For five years, Jo ran a successful consulting business, primarily facilitating local research organisations to develop strategy and plan major collaborative research projects.

Jo also designed and implemented a range of development programs for local and international markets. Her contributions expand to the fundraising and community development areas where Jo has driven a range of high-impact initiatives. Jo is currently Manager, Strategy Development, Health Technologies at Flinders University. She is a graduate of the Governor's Leadership Foundation Program and a scholarship recipient of the Australian Institute of Company Directors.

Jo commented, *"I am delighted to step up to the position of Chair and take on the role that David Coluccio has so exceptionally exemplified.*

Under his leadership, our focus as a board has been unwavering and our progress has been astounding. We are committed and united to supporting research that will transform the lives of those with cystic fibrosis. I am passionate about the cause and the solution – we need to fight for a cure for CF, and research is the answer."

Jo will take over as Chair of the Foundation in September 2018.

> "I AM PASSIONATE ABOUT THE CAUSE AND THE SOLUTION – WE NEED TO FIGHT FOR A CURE FOR CF, AND RESEARCH IS THE ANSWER."
>
> JO CLOSE, *CHAIR CURE4CF*

FROM THE EXECUTIVE MANAGER

SUZY DIMALINE, *EXECUTIVE MANAGER, CURE4 CYSTIC FIBROSIS*

It is my absolute privilege to address you as the Executive Manager of C4CF. I've been at this remarkable Foundation for just over 9 months now and have enjoyed being a part of an organisation with such purpose and transparency.

Leading C4CF is a mission that I embrace with respect and dedication. The fact that over 70,000 people could benefit from research supported by C4CF is an inspiration, as well as a source of pride.

What C4CF can do is relevant to people all around the world and the lofty goal we have set for ourselves is to raise the funds needed, to continue medical research that will lead to an eventual lifelong solution. I'm well aware of the importance of this task and of the tremendous responsibility I take on in serving our CF community.

C4CF will continue to be guided by the values for which we've always stood – impactful, collaborative, integrity, inspirational and passionate. These values make us strong and remind us of our commitment to them, as well as our community.

Since commencing with C4CF I've been amazed by the enthusiasm and generosity of our CF community. People who are willing to put their time, energy, skills and funds to bring us closer to a cure.

We've had an extraordinary year. Together, with the community we've raised more than $1M. That is the power of our army.

The last 12 months saw C4CF make its largest ever investment in CF research, directly benefiting the Cystic Fibrosis Airway Research Group (CFARG). Thanks to the Fay Fuller Foundation, the CFARG 'Discovery Project' is underway, enabling the team to further their work on a gene therapy cure for CF lung disease.

Our Community Fundraisers continued to play an invaluable role, increasing our reach and awareness and inspiring people to join the fight. Their efforts were seen and heard right around Australia, with one CF Warrior travelling as far as Antarctica! The Geelong Gala dinner once again proved to be the hottest ticket in town, well and truly exceeding its target and raising $86,000. An outstanding achievement in its third year.

Thanks to a 'Digital Innovation' grant from our friends at AHA Community Care, the Foundation was able to purchase and implement a database and CRM. It was a huge undertaking and I extend my gratitude to Jessica, who worked tirelessly to make this happen.

Continuing our digital innovation, we also implemented a new website. The creative geniuses at NATION, once again, went above and beyond to deliver a website which not only inspired purpose and engagement, but enabled the Foundation to reduce fees by hosting its own donation page. Heartfelt thanks to the ongoing generosity of Greg Knagge and his amazing team, this is just one of the many probono projects NATION has accomplished over the past 12 months.

Beyond Bank continued to show their community spirit by getting involved in a number of our fundraising endeavours. In September they'll wear their war stripes with pride and march alongside us in the City to Bay.

This year we also appreciated the wonderful efforts of our CF Ambassadors, who shared their resources, stories and voices to shine a spotlight on why we fight. I will be recruiting new volunteer Community Ambassadors around Australia to help grow our army at a local level and I look forward to sharing more about this project as it develops.

As we look forward to the coming 12 months, there is much to be excited about. New partnerships will see C4CF fund an exciting Phage Therapy study, which will focus on eliminating drug resistant bacteria in CF using bacterial phage. Human clinical trials are expected to take place in the second half of 2019.

We'll also begin our partnership with the National Foundation for Medical Research and Innovation (NFMRI), expanding our search across the country for promising cystic fibrosis research that support life extending therapies and cures. Our first NFMRI grant will be named the Barbara Stow-Smith CF Innovation Grant, in honour of the late Barbara Stow-Smith who bequeathed the Foundation it's very first bequest.

I'd like to acknowledge my colleagues, Jessica and Jodi who have hit the ground running, achieving much in a short amount of time. They bring a fierce combination of optimism, drive and determination to our Foundation and I feel very fortunate to work with such talented people.

Thanks to the board for their input and active service. Their collaborative efforts and commitment to the fight continue to strengthen our Foundation. I'd also like to take this opportunity to thank David Coluccio for his guidance, wisdom and support. His contribution to C4CF and the CF community has been outstanding and it has been a privilege to work alongside him. I look forward with excitement, to continuing working closely with Jo Close in her new role as Chair.

To our donors, Ambassador Circle members and partners, I am extremely grateful to each and every one of you. We simply would not exist without you. You give more than hope to our CF community, you allow them to picture what a future without CF could look like and it's because of you, this is a battle we are destined to win.

"WE'VE HAD AN EXTRAORDINARY YEAR. TOGETHER, WITH THE COMMUNITY WE'VE RAISED MORE THAN $1M.

THAT IS THE POWER OF OUR ARMY."

ABOUT CURE4 CYSTIC FIBROSIS FOUNDATION

FORMALLY ESTABLISHED IN 2009, OUR VISION IS A CURE FOR CYSTIC FIBROSIS (CF)

HOW WE SUPPORT A CURE

C4CF fund scientific research that seeks to develop therapies or cures that will result in a material increase in average life expectancy of people with cystic fibrosis.

To date this has included the work of the Cystic Fibrosis Airway Research Group (CFARG) as they work towards a cure for cystic fibrosis airway disease, employing a gene transfer approach.

A new partnership with the National Foundation for Medical Research and Innovation (NFMRI) will see C4CF expand its grant program to the national scientific research community. The broad reach of the NFMRI grant program to universities and medical research institutes across Australia, means that C4CF can achieve a long desired ambition to be aware of, and potentially fund, the best CF research initiatives across the country.

WHY WE NEED A CURE

CF is the most common, life-limiting, inherited disease affecting the developed world, with one in every 2,500 children impacted.

It's a multi-organ disease, affecting the lungs, gut, liver, pancreas and reproductive tissues. It impacts the system responsible for producing saliva, sweat, tears and mucus and can lead to a failure to thrive and malnutrition; as well as dehydration due to abnormally high sweat sodium and chloride levels.

Average life expectancy is just 38 years and although the symptoms and conditions of CF are variable between each person, lung disease and progressive respiratory impairment are the primary causes of morbidity and mortality.

From birth, the treatment and management of CF is life–long and intensive. Due to its complexity and multi–systemic involvement, there is a need for a range of specialists in the overall management of CF patients, with the annual cost to the Australian community to treat CF around $68 million.

Approximately 1 in 25 Australians are carriers of a genetic mutation responsible for CF.

Currently there is no cure.

ONE IN EVERY 2,500 CHILDREN ARE IMPACTED BY CYSTIC FIBROSIS.

C4 CF

JENSEN, CF WARRIOR

OUR BOARD

WHY WE FIGHT

DAVID COLUCCIO *(CHAIRMAN)*

We fight because it is our fight, and no one will fight it for us. We must never accept no for an answer, be prepared to be ridiculed, insulted and underestimated, and then fight like hell to get the job done.

JO CLOSE *(CHAIR ELECT)*

I'm all for the fight to support amazing, committed researchers (our heroes!) to do their best work and profoundly transform the lives of those with cystic fibrosis.

MAL CHIA

I fight to give those with CF and their families a chance to lead a better life and to find a cure in my lifetime.

JACINTA CONNELL

I believe that a world without CF is within our reach, and I am proud to stand alongside world leaders in medical research and members of the community in this passionate and tireless fight.

MARK EVANS

I believe we will find a cure for CF in my lifetime; I believe we are on the right track and I absolutely believe in medical research – and I am prepared to fight for that.

DEB HOSKING

Because together we will unite head on with all our abilities and work tirelessly to eliminate, prevent and overcome CF.

GREGG JOHNSON

People affected by CF fight against the disease to survive each day and I am proud to join them in my fight to find a cure.

LACHLAN MONFRIES

I fight for the resilient CF community and for my family who has been impacted by the disease in the past and will be in the future.

OUR BOARD

WHY WE FIGHT

GREG OKE

Having a son with CF drew our attention to the great burden that children, families and adults that have CF must endure. We want to do everything we can to help these people for the long term. We established Cure4 Cystic Fibrosis to help and we have seen great progress towards a cure over recent years.

JENNY PARADISO

Because my friend Ruth has CF, has survived a double-lung transplant and deserves a long, healthy life.

People affected by CF fight against the disease to survive each day and I am proud to join them in my fight to find a cure.

DUANE RIVETT

I fight to translate the ground-breaking gene therapy research into a product which will cure CF for life.

Because together we will unite head on with all our abilities and work tirelessly to eliminate prevent and overcome CF.

GREG SAVAGE

My involvement with the Cure4 Cystic Fibrosis board has allowed me to meet many inspiring people living with cystic fibrosis, I believe we will find a cure for this disease and I am up for the fight to support the medical research to deliver this life-changing cure.

MEGAN WEBSTER-BRADMAN

I passionately believe that life can be better for every person with CF and that a cure is achievable if our research has the resources it needs.

OUR TEAM

EXECUTIVE MANAGER

SUZY DIMALINE

Suzy has over 24 years experience in the not-for-profit industry, particularly within the disability and employment sectors. She has lent her expertise to roles with the MS Society of SA & NT, Women's & Children's Hospital Foundation and the Art Gallery of South Australia.

Suzy is an experienced multi-channel fundraiser, who specialises in driving income generation, donor development, stakeholder engagement and managing teams.

Suzy is excited to join the fight and partner with the cystic fibrosis community to advance a cure.

'CF robs people of their basic human right to life. I fight to give it back and research is the solution.'

DONOR DEVELOPMENT MANAGER

JESSICA BUCKLEY

Jessica is an experienced fundraiser, having worked for over 9 years in the not-for-profit industry in Australia and the UK. She has worked for Women's & Children's Hospital Foundation, PriceWaterhouseCoopers, LLP and the University of Adelaide.

Jessica specialises in database management, data analysis and donor engagement, and is solutions focused with a strong analytical mind.

As a carrier of the CF gene, Jessica is excited to join the fight to help find a cure for cystic fibrosis, a cause close to her heart having grown up with a friend with it and seeing the effects it has on individuals and their families.

'I fight for those who can't, because they're fighting for their lives. We need to fight for them because I believe there will be a cure.'

MARKETING AND COMMUNICATIONS MANAGER

JODI FARLEY

Jodi has worked for over 15 years in the not-for-profit sector in South Australia and Northern Territory.

Specialising in stakeholder engagement, communications and strategic planning, as well as leadership and mentoring, Jodi possesses a natural ability to develop authentic and meaningful partnerships. Jodi previously worked at CanTeen in various roles including State Manager SA & NT and State Partnerships Manager, where her key responsibilities included community relations and awareness, collateral development, media and sponsorship management.

Jodi is passionate about driving social impact and looks forward to connecting with the CF community and working with them in support of a cure. She is proud to be All4TheFight.

'I am part of the fight because every person with CF deserves a life free from this disease. Together, we can make a collective impact greater than any single individual could ever imagine. We won't give up until we find a cure.'

OUR AMBASSADORS

JAMIE SACH

PENFOLDS GLOBAL AMBASSADOR

Jamie Sach continues to show he is all for the fight against CF by working tirelessly to help find a cure for a disease that personally affects his family.

MAE JOHNSON

CURE4CF YOUTH AMBASSADOR

Our Youth Ambassador Mae, who is living with CF, fights for a cure by being a great role model for her peers, and by raising awareness in the community.

EMMAH EVANS

CF MUMMY

Emmah embodies the word ‘fighter’ and through her story inspires others. Living with CF, Emmah fights every day to stay healthy so she can raise her two children and fight for a cure.

MELISSA HAYNES

ATHLETE

Melly is a talented athlete living with CF and continues to inspire those around her with her energy and enthusiasm to fight for a cure.

REBECCA MORSE

NETWORK TEN NEWSREADER

Bec fights for a cure so all kids can live long and happy lives without struggling for breath. And so no parent will have to watch their child suffer from this cruel disease.

ANGUS MONFRIES

FORMER PORT ADELAIDE FOOTBALL CLUB PLAYER

Angus Monfries has every reason to fight for a cure after seeing the effects of CF on his family. Just as he did on the football field, Angus brings a great deal of passion and enthusiasm to our cause.

2017/18 SNAPSHOT

C4CF REVENUE



HOW YOUR DONATIONS ARE INVESTED

For every $1 raised or given, approximately 81 cents is available to fund existing and future research projects, 3 cents is invested back into fundraising programs to generate more revenue, and approximately 16 cents is used to ensure we have the right people and systems in place to support our Foundation.



INVESTMENT IN RESEARCH



IN 2017/18 YOU HELPED US RAISE MORE THAN $1 MILLION



THANK YOU TO THE 1,000+ INDIVIDUALS AND ORGANISATIONS WHO SUPPORTED OUR WORK



OVER $780K INVESTED IN CF RESEARCH

HOW WE INVESTED IN RESEARCH

HOW CURE4 CYSTIC FIBROSIS INVESTED IN RESEARCH

In 2017/18 we invested more than $780K in scientific research through our grant funding program. This was the largest investment in the Foundation's history, an achievement we are extremely proud of.

Of those funds, more than $750K was invested in direct grants to the Cystic Fibrosis Airway Research Group (CFARG). Our funding supported the group to continue projects, which will contribute to the global body of knowledge, that will lead to better treatments and measurements.

Thanks to the generosity of the C4CF supporters, CFARG were able to utilise the funding in the following ways:

- Direct funding support for staff;
- Purchases of critical equipment;
- Funding for important national and international conferences;
- Travel to Japan to conduct important imaging studies at the SPring-8 Synchrotron near Osaka;
- Direct funding of a research administrator to undertake much of the administrative requirements of the group and free research scientists to focus on research activity;
- Funding of PhD scholarships for talented students interested in pursuing research into cystic fibrosis;
- Provision of a research consultancy to assist the team in planning a critical pathway of research activity required to take the research program to human clinical trials.

Significant advancements made by the CFARG during the past ten years have only been possible through the support of C4CF and its philanthropic partners.

Some of the key outcomes delivered as a result of funding provided by C4CF include:

- Undertaking a pre-clinical trial that demonstrated a lifelong gene correction in a mouse model utilising the lentiviral gene vector. This was the first time the outcome was achieved anywhere in the world.
- Participation in collaboration with a team from Monash University, in the development of Computed Tomographic X-ray Velocimetry (CTXV) imaging technology that is now coming to market and provides a four-dimensional view of living lung tissue. This will greatly improve the diagnosis and treatment of a range of respiratory diseases.
- The establishment of an Australian CF rat colony which, for the first time, will allow the research group to rapidly and routinely perform gene therapy studies to provide disease-specific guiding data for translation to human use.

THE IMPACT OF OUR INVESTMENT

FOCUS OF OUR FUNDING IN 2017/18

The Cure4 Cystic Fibrosis Foundation remains the only one of its kind in Australia solely dedicated to funding a cure for CF.

The support our Foundation provided to the Cystic Fibrosis Airway Research Group (CFARG) has been the largest to date and in 2017/18 we fought to help ensure the progress of their work.

This year CFARG devoted more than 20,700 hours in the pursuit of a cure for cystic fibrosis. A phenomenal achievement.

As they continue to work toward their milestones, there have been some exciting achievements. Particularly around the establishment of the first ever cystic fibrosis lung disease model (CF Colony) in Australasia, which has allowed them to test and measure the effectiveness of corrective gene therapy on a living lung.

CFARG PROJECTS OUR SUPPORT HAS CONTRIBUTED TOWARDS

INCUBATOR GRANT

This grant has supported the ongoing development of an airway gene therapy cure for the lung disease of cystic fibrosis.

PROJECTS:

1. Development of an airway gene therapy cure for the lung disease of cystic fibrosis.
2. Assessing the effects of CFTR gene delivery on airway surface hydration and local lung function.
3. Assessing the effectiveness of lentiviral airway gene therapy for cystic fibrosis disease in various animal models *in vivo*.
4. Lentiviral gene vector production.
5. Modification of lentiviral vectors for improved tracking and safety.
6. Assessing lentiviral vector treatment strategies for CF airways to maximise short and long-term outcomes.

FAY FULLER DISCOVERY GRANT

This grant has supported studies in a new animal model with appropriate CF lung disease: the CF rat. The project will enable measurement of localised changes in lung function that result from gene vector delivery and help further develop and refine an effective CFTR gene-delivery system for CF lungs.

PROJECTS:

1. Current state of the CF rat breeding colony
2. Overview of pathology in the 508 and 512X CF rats
3. Reporter gene studies in rat lungs
4. X-ray based lung health measurement experiments

CFARG TEAM OF 2017/18

RESEARCHERS:

Director - A/Prof David Parsons; Co-Director - Dr Martin Donnelley; Dr Trish Cmielewski; Dr Chantelle McIntyre; Dr Nathan Rout-Pitt; Dr Juliette Delhove; Dr Nigel Farrow; Dr Freda Werdinger (Monash University)

RESEARCH ADMINISTRATION AND SCIENTIFIC SUPPORT:

Ms Bernadette Boog

PHD STUDENTS:

Mr Ryan Green; Ms Harsha Padmanabhan, Ms Ali McCarron

HONOURS STUDENT:

(PhD in 2018): Ms Chanty Carpentieri

THE IMPACT OF OUR INVESTMENT

INCUBATOR GRANT PROJECTS

Selected key milestones completed within the period were:

1. DEVELOPMENT OF AN AIRWAY GENE THERAPY CURE FOR THE LUNG DISEASE OF CYSTIC FIBROSIS

- Establishment of five new Australian CF research collaborative links utilising CF rats and rat tissue samples. David Parsons is currently interacting with two national and one international CF research groups to establish new collaborative studies using our Adelaide CF rats. These include learning the techniques for producing bronchospheres that could be used for genetic therapy testing.

2. ASSESSING THE EFFECTS OF CFTR GENE DELIVERY ON AIRWAY SURFACE HYDRATION AND LOCAL LUNG FUNCTION

- Completion of CTXV (Computed Tomography X-ray Velocimetry) imaging experiments at the Australian Synchrotron. This experiment was designed to show that local lung function changes produced by Pseudomonas infection are detectable via CTXV, and that their location within the lung can be identified. The experimental work was completed 31st March 2018, with data analysis continuing.
- Completion of airway imaging experiments at SPring-8 X-ray Synchrotron in Japan. These experiments were designed to determine whether CF rats have reduced ASL height and/or mucus clearance. The experiments began 20th June 2018 and are underway.

3. ASSESSING THE EFFECTIVENESS OF LENTIVIRAL AIRWAY GENE THERAPY FOR CYSTIC FIBROSIS DISEASE IN VARIOUS ANIMAL MODELS *IN VIVO*

- Completion of all students and staff being competent in aspects of in-vivo airway gene therapy in animal models. This milestone was completed in April 2018 with current staff trained in standard *in vivo* gene therapy techniques. However, as new techniques are established, and as new staff enter CFARG, training will be a continually updated as required.
- Completion of the potential difference (PD) measurement technique in rat nasal airways. The PD technique (for measuring change in CFTR function in airways) was successfully translated from mice into rat nasal airways. PD's on the three CF rat strains and their normal littermates have been completed and analyses finalised in June 2018, demonstrating that the null CF rats (rats bred without the CFTR gene in their body) have a more severe phenotype compared to rats with the Phe508del, in regard to ion channel defects in nasal airways. This data will be included in a CF rat characterisation publication.

4. LENTIVIRAL GENE VECTOR PRODUCTION

- LacZ and CFTR vector for initial rat dosing studies. Initial testing of vector in the new CF rat model required the production of two separate types of vector initially but due to the bronchoscopic delivery method, a third batch was made. Additional LacZ vector was required to test and optimise a range of factors including the correct delivery dose - volume, the spread of transduction throughout the lung, and the types of cells transduced. Vector was also made specifically to test the team's new bronchoscopic delivery method to a single lung lobe.
- Large-scale production of lentiviral vectors using multilayer cell factories. Due to the increased volume of vector required to dose larger animal models (marmosets and rats), the vector production protocol was upscaled. These changes were significant enough that they warranted the creation of a specific Methods paper, and that paper has now been published.

5. MODIFICATION OF LENTIVIRAL VECTORS FOR IMPROVED TRACKING AND SAFETY

- Vector safety studies. Three versions of lentivector were generated for safety testing. The 3rd generation version is the current gold standard for clinical trials and would be our clinically-appropriate vector version. The final construct and its resulting vectors are now more compliant with standards required by the Therapeutic Goods Administration (TGA) for human use. This development aligns with a major part of the CFARG critical path.
- The vector was tested in vitro (February 2018) and *in vivo* (March 2018).
- CFTR gene vector was produced and administered to CF mice (June 2018), as a prelude to the testing of CF gene transfer in CF rats. Confirmation of expression and functional correction in a CF mouse model is ongoing and is currently underway, led by Dr Patricia Cmielewski (June 2018).
- This vector was used in a bioreactor production by Ali McCarron, and for the first time administered to rats. Data acquisition is ongoing.

6. ASSESSING LENTIVIRAL VECTOR TREATMENT STRATEGIES FOR CF AIRWAYS TO MAXIMISE SHORT AND LONG-TERM OUTCOMES

Two papers were published from work in this area:

- Submission and acceptance of manuscript *"Role of Basal Cells in Producing Persistent Lentivirus-Mediated Airway Gene Expression"* in Human Gene Therapy: Submitted and accepted in 2017, published online in January 2018 and in the print edition in June. The study was highlighted in the editorial by the the Editor in Chief of the Journal, highlighting a renewal of the importance and the potential for use of gene therapies in treatment of cystic fibrosis.
- Submission and acceptance of manuscript *"Epithelial disruption. A new paradigm enabling human airway stem cell transplantation"* in Stem Cell Research and Development. Published June 13, 2018.
- Laboratory visit at the Somatic Stem Cell Centre at the University of Houston (Professor Frank McKeon).

THE IMPACT OF OUR INVESTMENT

FAY FULLER FOUNDATION DISCOVERY GRANT REPORT

SIGNIFICANT OUTCOMES

- The CF rat physiology validation is 90% complete
- Successfully tested regional gene vector delivery
- CFTR gene addition trials have begun
- X-ray development testing in normal rats has been successfully completed
- X-ray imaging studies of ASL and MCT are underway at SPring-8 in Japan

Some key milestones completed within the period were:

I. CURRENT STATE OF THE CF RAT BREEDING COLONY

- The team is currently maintaining two different breeding lines of CF rat within the CF rat colony. One breeding line carries the most common CF causing mutation in the human population, phe508del, while the other breeding line carries a frameshift/ termination mutation that is equivalent to a type I/VII CF mutation in the human population, resulting in a knockout (KO, also called 'null') CF rat. The first CF rats produced by the colony were born in June 2017. At June 2018 the team had generated more than 50 CF rats for each of these two different genotypes.

2. OVERVIEW OF PATHOLOGY IN THE PHE508DEL AND 5I2X CF RATS

- The team has started characterising these rats through observational studies (such as recording breeding and mortality rates, and body weights), functional studies (including nasal potential difference measurements, flexiVent lung function assessment, and synchrotron imaging studies), histological assessments, and RNA analyses.

3. REPORTER GENE STUDIES IN RAT LUNGS

- In preparation for gene therapy studies in these CF rats, the team performed a series of lung-targeted gene delivery experiments in normal rats using the marker gene LacZ, which produces a blue product to allow for the visualisation of gene-modified cells. The marker gene was used to test and optimise procedures before they test the CFTR gene, since expression of the CFTR gene cannot be easily detected, and its effects are harder to measure. Using a miniature endoscope, which was purchased late in 2017, via a grant from the Cure4 Cystic Fibrosis Foundation, the team developed a method to target gene delivery to individual lung lobes, and have demonstrated this technique to be accurate and reproducible. A publication about this novel lung dosing technique has been accepted by the journal Human Gene Therapy.
- The team's findings from the reporter-gene delivery studies, have confirmed the effectiveness of lentiviral gene delivery into rat lungs. Preliminary testing of CFTR gene delivery began in June and the team is poised to begin the significant CFTR gene-addition studies of the FFF project in the coming months.

4. X-RAY IMAGING EXPERIMENTS

- In March 2017 the team successfully performed the first of three linked experiments at the Imaging and Medical Beamline at the Australian Synchrotron to assess whether local airflow changes produced by sterile bead delivery are detectable by our Local Airflow Analysis (LAA) algorithms. In the August 2017 experiment they extended this study and examined clearance of beads by assessing groups of rats at different time points after dosing. In March 2018, they examined the effect of delivery Pseudomonas aeruginosa (PA) containing beads to the airways of normal rats. Data analyses from all these studies are in progress (performed by external team member Dr Freda Werdiger, Monash University).

CFARG SUBMITTED/ACCEPTED PUBLICATIONS

INCUBATOR GRANT

A. McCarron, D. Parsons, M. Donnelley,
https://doi.org/10.1186/s12931-018-0750-y
"Airway disease phenotypes in animal models of cystic fibrosis", Respiratory Research, vol. 19:54, 2018.

N. Rout-Pitt, A. McCarron, C. McIntyre, M. Donnelley, D. Parsons,
https://doi.org/10.14440/jbm.2018.236
"Upscaling the production of a VSV-G pseudotyped lentiviral vector using cell factories", Journal of Biological Methods, vol. 5(2):e90, 2018.

C. McIntyre, M. Donnelley, N. Rout-Pitt, D. Parsons, "*Lobe-specific gene vector delivery to rat lungs using a miniature bronchoscope"*, Human Gene Therapy, Accepted for publication, June 2018.

N. Rout-Pitt, N. Farrow, D. Parsons, M. Donnelley, *"Epithelial-Mesenchymal Transition (EMT): A universal process in lung diseases with implications for cystic fibrosis pathophysiology"*, Respiratory Research, Accepted for Publication, 2018.

N Farrow, P Cmielewski, M Donnelley, N Rout-Pitt, Y Moodley, I Bertoncello and D Parsons
https://doi.org/10.1186/s13287-018-0911-4
"Epithelial disruption: a new paradigm enabling human airway stem cell transplantation." Stem Cell Research & Therapy (2018) 9:153

R. Gradl, M. Dierolf, B. Gunther, L. Hehn, W. Moller, D. Kutscheke, L. Yan, M. Donnelley, R. Murrie, A. Erl, T. Stoeger, B. Gleich, K. Achterhold, O. Schmid, F. Pfeiffer, K. Morgan,
https://doi.org/10.1038/s41598-018-24763-8
"In-vivo Dynamic Phase-Contrast X-ray Imaging using a Compact Light Source", Scientific Reports, vol. 8, 6788, 2018.

M. Donnelley, M. Klein, D. Hausermann, C. Hall, A. Maksimenko, K. Morgan, D. Parsons, *"Live pig airway surface imaging and whole-animal CT at the Australian Synchrotron Imaging and Medical Beamline"*, Journal of Synchrotron Radiation, Under review, 2018.

H. Jung, S. Lee, M. Donnelley, D. Parsons, I. Lee, V. Stamatescu, *"Multiple marker particle tracking in Synchrotron time-lapse X-ray images for assessment of mucociliary clearance in live mouse nasal airways"*, Medical Image Analysis, Under review, 2018.

FAY FULLER DISCOVERY GRANT

A. McCarron, D. Parsons, M. Donnelley,
https://doi.org/10.1186/s12931-018-0750-y
"Airway disease phenotypes in animal models of cystic fibrosis", Respiratory Research, vol. 19:54, 2018.

N. Rout-Pitt, A. McCarron, C. McIntyre, M. Donnelley, D. Parsons,
https://doi.org/10.14440/jbm.2018.236
"Upscaling the production of a VSV-G pseudotyped lentiviral vector using cell factories", Journal of Biological Methods, vol. 5(2):e90, 2018.

C. McIntyre, M. Donnelley, N. Rout-Pitt, D. Parsons, *"Lobe-specific gene vector delivery to rat lungs using a miniature bronchoscope"*, Human Gene Therapy, Under review, 2018.

I AM DOING EVERYTHING I CAN TO BE PART OF THE CURE TO TRY AND HELP SAVE MY CHILD'S LIFE. THIS GIVES ME PURPOSE AND HOPE.

JENSEN, CF WARRIOR
AND HIS MUM FIONA

C4 CF

NEW PARTNERSHIPS

EXPANDING OUR REACH

NATIONAL FOUNDATION FOR MEDICAL RESEARCH AND INNOVATION (NFMRI)

In 2019, Cure4 Cystic Fibrosis will join forces with the National Foundation for Medical Research and Innovation (NFMRI), a not-for-profit company that provides research grants to research organisations to achieve its mission.

This partnership will see NFMRI, who receive advice and recommendations from an established Research Advisory Committee, manage and administer grants on behalf of C4CF.

For the first time, we will offer grant funding opportunities to a competitive research market, Australia wide.

Our scope is to fund research that develops therapies or cures that will result in a material increase in average life expectancy of people with cystic fibrosis with consideration given to quality of life.

Our partnership with NFRMI will see C4CF expand its grant program to the national scientific research community. The broad reach of the NFMRI grant program to universities and medical research institutes across Australia means that C4CF can achieve a long-desired ambition to be aware of, and potentially fund, the best CF research initiatives across the country.

Through collaboration with our CF community and investment in research we will help strengthen and expediate the delivery of research outcomes, i.e. tangible products and treatments.

Expressions of interest will be called in three key gap areas known as social investment portfolios. Each of these portfolios supports research that falls within these gaps in order to help translate innovations through to next stages, so they may ultimately reach the community.

- **PORTFOLIO 1** – Original innovation and discovery supports research projects that have interesting and serendipitous findings but without enough data validation to support a National Health and Medical Research Council (NHMRC) grant. NFMRI will provide grants to generate data validation that will either fail the project or increase its chances of an NHMRC grant.
- **PORTFOLIO 2** – Collaborative innovation and advancement - provides grants for research projects that requires them to engage experts and scientists outside of their institution of employment.
- **PORTFOLIO 3** – Innovation uptake and transformation focuses on the ‘valley of death’. It is pre-commercialisation and addresses the external research questions required to attract a collaborator/ industry investment or to meet translational requirements.

NFMRI has more than $23M in funds under management and disburses approximately $1M per annum through its own grant program. Where it is aligned with their program, or where projects are compelling, NFMRI may use its own funds to top-up or provide additional funding to projects selected for its funding partners.

Our combined potential impact is powerful and could have far reaching effects on the cystic fibrosis community. We look forward to providing you with exciting updates as this partnership develops.

ADELAIDE ENT RESEARCH TEAM - RESEARCH TRIAL AT BASIL HETZEL INSTITUTE

Funded by C4CF, Cystic Fibrosis South Australia and The Hospital Research Foundation, the Adelaide ENT Research Team commenced a new Phage Therapy project in July 2018, which aims to eliminate drug resistant bacteria in CF using bacterial phage.

The key cause of early death of people with CF is the inability to control and eliminate drug resistant, deadly bacteria in the lungs. People with CF develop resistance to these bacteria because of their dependency on antibiotics, which become less effective over time. Once the deadly bacteria has developed a resistance to antibiotics, health declines, and the work required to control the disease increases significantly.

What’s especially exciting about this project is that it doesn’t have to start with the basics. It’s building on Phage Therapy research that existed in the 1940’s.

Professor Wormald, who is leading the team said, *“My team is very excited about new research that shows (in the laboratory setting) we are able to almost completely eliminate multi-drug resistant staphylococcus bacteria with a new bacteriophage-based therapy whereas this was not possible with currently available antibiotics. This research has great potential to be of significant benefit to the cystic fibrosis patient group who are constantly battling very difficult to treat infections. We envisage a phase 1 clinical trial in the second half of 2019.”*

This work is being carried out in three separate studies:

- Optimisation of the delivery of phage and antibiotics;
- Safety and efficacy study in our sheep model of sinusitis;
- Phase 1 Human clinical trial in cystic fibrosis patients.

This is exciting research and has been described as a ‘game changer’ for the CF community. We look forward to keeping you updated as this research progresses.

‘FOR THE FIRST TIME WE WILL OFFER GRANT FUNDING OPPORTUNITIES AUSTRALIA WIDE’.

COMMUNITY FUNDRAISING

TOGETHER WE FORM A REMARKABLE FORCE

We celebrate the passionate individuals who united together and showed what can be achieved when we stand as one. Raising more than $185K to invest in research, our Community Fundraisers walked, ran, danced, swam, partied, golfed, quizzed and lunched their way around Australia, raising funds and awareness for CF research.

RUBY & SAVANNAH

Amanda Lowe and Rachel Smart once again raised funds during CF Awareness Month, raising more than $5,000 for research in support of CF Warriors Ruby and Savannah.

WHYALLA GOLF DAY AND DINNER

David McOmish & Richelle Bond held their first Whyalla Golf Day and Dinner event which was a great success raising over $14,500.

LION'S WALK – THOMAS FAMILY

The Thomas family from QLD held their annual Lions Walk in support of CF Warrior Leo, and raised over $4,000 from their fundraising efforts in May.

CRAZY HAIR DAY – LOBETHAL LUTHERAN SCHOOL

For their service and leadership day, staff and students at Lobethal Lutheran School got crazy with their hair and raised $523.

COMMUNITY FUNDRAISING

TOGETHER WE FORM A REMARKABLE FORCE

GO RED 4 FEB – ROBINS FAMILY

Team Robins and their army of supporters raised $8,900 in the QLD Go Red 4 Feb campaign in support of CF Warrior James.

JENNY TAYLOR – POLAR PLUNGE

Inspired by a friend's son who has cystic fibrosis, the brave Jenny Taylor plunged into the freezing waters of Antarctica, raising $5,550 in support of a cure.

CHARITY & FUN FOR EVERYONE – JENNY JURY & JAN DALTON

A wonderful effort from Jenny, Jan and Belinda from Charity and Fun for Everyone, saw them raise $15,000 in support of CF research at this year's CF Ladies Lunch.

MELLY HAYNES – NY MARATHON

The amazing Melissa Haynes, 29 years old and living with CF, ran a staggering 42.195 km to complete the New York Marathon, raising $6,600 for CF research.

GOLDENGROVE GOLF DAY

COMMUNITY FUNDRAISING

TOGETHER WE FORM A REMARKABLE FORCE

GOLDENGROVE GOLF DAY

Thanks to our new friends at Goldengrove Building Group and Favero Property Corporation, who together donated over $16,000 from their annual golf day.

AFL LAUNCH LUNCH

Thanks to The Advertiser Foundation who chose C4CF as their Charity Partner for their annual AFL Season Launch Lunch and donated $20,000.

CF GEELONG GROUP – GALA DINNER

The Geelong CF Support Group raised an amazing $86,000 from their third annual Gala Dinner attended by 530 guests.

BECAUSE OF OUR COMMUNITY THIS IS A BATTLE WE ARE DESTINED TO WIN.

SISTERS OLIVIA AND ELLIE-MAY, CF WARRIOR
AND THEIR DAD GREG

JOIN THE FIGHT

HOW YOU CAN HELP

MAKE A DONATION

Your gift, of whatever you can afford, will make a real difference. Donate online at cure4cf.org or, look out for ‘Tap N Go’ donation devices at events and supporting local businesses.

FUNDRAISE FOR US

Pick a challenge and start fundraising for a cure. It could be the Adelaide City to Bay, Bridge to Brisbane or Run Melbourne, we have lots of options.
Register at cure4cf.org

HOST AN EVENT FOR US

Got a great idea to raise funds for CF research? Why not host a fundraising event for us and we’ll provide you with the tools you need to ensure it’s a great success?
Sign up at cure4cf.org

BECOME A REGULAR DONOR

Become a part of the army who regularly donate either weekly, monthly or annually and join the CF Fight Club. As little as $5 each month can make a big difference to research we back. Sign up at cure4cf.org

REMEMBER US IN YOUR WILL

Leave a lasting legacy through investment in research by leaving a gift to C4CF in your will. Contact our friendly staff for more information.

‘YOU CAN BE A PART OF THE CURE’

JOIN THE AMBASSADOR CIRCLE

Our Ambassador Circle plays a vital role in our pathway towards a cure. A high impact collective circle of giving, each member contributes $12,000 per annum to be invested in CF research.

BECOME A CORPORATE PARTNER

Our corporate partners contribute their time, energy, skills and funds to bring us closer to a cure. We have many options from sponsorship or cause related marketing to workplace giving. A partnership with C4CF will have an impact.

HOST A ‘TAP N GO’ DONATION DEVICE

Hosting a device is a no cost way businesses can support CF research and it’s simple to get started, just plug the device into a USB or power point and you’re ready to ‘tap and go’. It works just like Pay Wave, except the donations come directly to C4CF.

ADVOCATE FOR US

Use your social profile to help us raise awareness about the need for a cure for cystic fibrosis. We believe that a world without CF is within our reach and that research is the answer. If you believe this too, join us in our fight.

OPEN A COMMUNITY REWARDS ACCOUNT

Open a Community Rewards Account with Beyond Bank. The more you save, the more interest you earn and the more money Beyond Bank will donate to C4CF, at no cost to you. Find out more at beyondbank.com.au/community-banking.

TAP N GO

PARTNERS AND ACKNOWLEDGEMENTS

IN 2017/18 OUR PARTNERS CONTRIBUTED MORE THAN $583K TO FUND MULTIPLE RESEARCH PROJECTS

FAY FULLER FOUNDATION

In 2016, the Fay Fuller Foundation granted C4CF Foundation $670,000 over 2 years to commence the ‘Discovery Project’. This funding has enabled us, for the first time anywhere, to test and measure the effectiveness of corrective gene therapy on a CF lung disease model.

GANDEL PHILANTHROPY

Gandel Philanthropy recently awarded C4CF $167,000 to fund the appointment of an X-Ray Lung Functioning Imaging Analyst based at Monash University and the Australian Synchrotron. This will enable mass data generated through research to be deciphered.

BEYOND BANK

Beyond Bank is a wonderful supporter of C4CF and continues to stand alongside us in the fight for a cure. They do this by participating in the Ambassador Circle, the Kickstarter Grants program and via their Community Rewards Program. In September, we will join forces at the 2018 City to Bay.

HACKETT FOUNDATION

The Hackett Foundation has been a generous supporter of C4CF since 2014 and over the last two years has donated over $265,000 in support of CF research.

NATION CREATIVE

Since 2017, NATION Creative has provided pro-bono marketing and advertising services and support valued at over $100,000 per annum. Their desire to make a difference in the CF community is clearly visible in the quality of their work and evident in the transformation of the C4CF brand.

AHA SA – COMMUNITY CARE PROJECTS

In 2018, AHA funded the C4CF Digital Innovation project. This saw the Foundation purchase and implement a database and CRM system, re-develop its website and purchase seven electronic ‘Tap n Go’ donation devices, which has introduced a new income stream for the Foundation.

PARTNERS AND ACKNOWLEDGEMENTS

C4CF WOULD LIKE TO THANK AND ACKNOWLEDGE ALL THE DONORS, COMMUNITY FUNDRAISERS, PARTNERS AND TRUSTS AND FOUNDATIONS WHO HAVE SUPPORTED OUR CAUSE IN 2017/18. OUR ARMY IS TOO BIG TO LIST EVERYONE INDIVIDUALLY, HOWEVER WE HOPE YOU KNOW HOW VERY GRATEFUL WE ARE.

Advertiser Sunday Mail Foundation

Alliance Timber

AMP Foundation

A Monfries

Australian Executor Trustees

B Gulliver

Beyond Bank Australia Foundation

Bittn Pest Control

B Oke

B & M Chapman

Carisbrook Crash Repairs

Charity and Fun for Everyone

Chill Shareholder Family Trust

CSL Transhipment Whyalla

Cystic Fibrosis Geelong Fundraising Events Group

D & P McKee

D McOmish

Davidsons Accountants

D Montgomery

D Dunn

E Evans

Fay Fuller Foundation

Gandel Philanthropy

Getaways SA

Goldengrove Building Group

Grace Children's Therapy

G Knagge

Hackett Foundation

Highline Caravans

Hosking Foundation

I & P Wall

J Close

J Dalton

J Pole

J Taylor

J Walding

Just Cars

K & C Robins

K Thomas

L Monfries

Lobethal Lutheran School

Macquarie Finance

Macquarie Group Foundation

McGuinness Media

M Haynes

Moffat Food Service

M & K Steele

M Rossiter

M Webster Bradman

Nisbet

Penfolds

P & F Thornborrow

Precision Plastering

Prince Alfred College

Raw Pearls

Real Gold (Gold Coast) Pty Ltd Favero

Roband

Robot Coupe

R Thomas

R Menzies

Rotary Adelaide

S Zadow

Slappa Thongs

Techne Developments

The Estate of B Stow-Smith

Tenison Place Early Learning

Tremul Constructions

Westminster Lutheran School

Winterhalter Australia

WE WILL WEAR OUR BATTLE SCARS AS ARMOUR AND FACE THIS DISEASE HEAD ON.

SIBLINGS ELISA AND BRODY, CF WARRIOR
AND THEIR DAD STEVEN

FINANCIAL REPORT CONTENTS

FINANCIAL REPORT

FOR THE YEAR ENDED 30 JUNE 2018

Your directors present this report on the company for the financial year ended 30 June 2018.

DIRECTORS

The names of each person who has been a director during the year and to the date of this report are:

Malcolm John Kai Wen Chia appointed (7/02/2018)
Joanna Kate Close David Coluccio Mark Robert Evans
Debbie Joy Hosking resigned (18/12/2017) Gregg Robertson Johnson
Lachlan Grey Monfries Gregory Lancelot Oke Jenny Paradiso
Duane John Rivett resigned (5/04/2018) Gregory Colin Savage
Megan Kate Webster-Bradman

Directors have been in office since the start of the financial year to the date of this report unless otherwise stated.

PRINCIPAL ACTIVITIES

The principal activity of the company during the financial year was:

Cure4CF Foundation's principal activity during the financial year was the raising of funds to support raising awareness of cystic fibrosis airway disease and research into the development of a cure.

INFORMATION ON DIRECTORS

Malcolm John Kai Wen Chia	Director
Qualifications	BCom, MCom
Joanna Kate Close	Director
Qualifications	Bbiotech (Hons), FGLF
Special Responsibilities	Deputy Chairwoman (appointed 7 June 2017)
David Coluccio	Director
Qualifications	BA, MA (IntSt), MBA, GAICD
Special Responsibilities	Chairman (non-executive) (appointed 2 December 2010)
Mark Robert Evans	Director
Gregg Robertson Johnson	Director
Qualifications	CA, Bcom, AssDip, MechEng
Lachlan Grey Monfries	Director
Qualifications	Bcom, MBA
Gregory Lancelot Oke	Director
Qualifications	BAppSc, MBA, MCIPS
Jenny Paradiso	Director
Qualifications	BA (Lib & InfoMgmt), GradDip (Comp & InfoScience)
Gregory Colin Savage	Director
Qualifications	Bcom, GradDipBusAdm
Megan Kate Webster-Bradman	Director
Qualifications	BA, LLB (hons), MPA

FINANCIAL REPORT

FOR THE YEAR ENDED 30 JUNE 2018

Your directors present this report on the company for the financial year ended 30 June 2018.

MEETINGS OF DIRECTORS

During the financial year , six meetings of directors were held. Attendances by each director were as follows:

	Directors' Meetings	
	Number eligible to attend	Number attended
Malcolm John Kai Wen Chia	3	2
Joanna Kate Close	6	6
David Coluccio	6	6
Mark Robert Evans	6	4
Debbie Joy Hosking	3	3
Gregg Robertson Johnson	6	6
Lachlan Grey Monfries	6	6
Gregory Lancelot Oke	6	6
Jenny Paradiso	6	5
Duane John Rivett	5	4
Gregory Colin Savage	6	3
Megan Kate Webster-Bradman	6	5

The company is incorporated under the Corporations Act 2001 and is a company limited by guarantee. If the company is wound up, the constitution states that each member is required to contribute a maximum of $10 each towards meeting any outstanding obligations of the company. At 30 June 2018, the total amount that members of the company are liable to contribute if the company is wound up is $100 (2017: $120).

AUDITOR'S INDEPENDENCE DECLARATION

The lead auditor 's independence declaration for the year ended 30 June 2018 has been received and can be found on page 3 of the financial report.

This directors' report is signed in accordance with a resolution of the Board of Directors.

Director

David Coluccio

Dated this Wednesday12th day of September 2018

AUDITOR'S INDEPENDENCE DECLARATION TO THE DIRECTORS OF CURE4CF FOUNDATION LIMITED

I declare that, to the best of my knowledge and belief, during the year ended 30 June 2018, there have been:

(i) no contraventions of the auditor independence requirements as set out in the Corporations Act 2001 in relation to the audit; and

(ii) no contraventions of any applicable code of professional conduct in relation to the audit.

Adam Drabsch
Director
Adelaide
12th September 2018

sjn Chartered Accountants
ABN 29 191 937 410
1 Alexandra Avenue
Rose Park, SA 5067
PO Box 410
Glenside, SA 5065
P: 08 8333 7300
F: 08 8333 7301
info@sjnca.com.au
www.sjnca.com.au

FINANCIAL STATEMENTS 2017/18

FOR THE YEAR ENDED 30 JUNE 2018

Statement of Profit or Loss and Other Comprehensive Income
For the year ended 30 June 2018

	Note	2018	2017
		$	$
Revenue	2	**845,358**	1,088,183
Other income	2	**15,366**	5,520
Employee benefits expense		**(143,475)**	(86,862)
Audit, legal and consultancy fees		**(6,904)**	(25,076)
Marketing expenses		**(26,282)**	(53,022)
Wine expenses		**(12,930)**	(10,921)
Administration expenses		**(19,199)**	(14,288)
Interest and financial expenses		**(1,790)**	(2,002)
Grant expenditure		**(792,299)**	(330,763)
Travel expenses		**(2,943)**	-
IT expenses		**(4,960)**	-
Current year surplus/(deficit) before income tax		**(150 ,058)**	570 ,769
Income tax expense			
Net current year surplus/(deficit)		**(150,058)**	570,769
Other comprehensive income			
Total other comprehensive (losses)/income for the year			
Total comprehensive income for the year		**(150,058)**	570,769
Profit/(loss) attributable to members of the entity		**(150,058)**	570,769
Total comprehensive income attributable to members of the entity		**(150,058)**	570,769

The accompanying notes form part of these financial statements.

Statement of Financial Position
As at 30 June 2018

	Note	2018	2017
		$	$
ASSETS			
CURRENT ASSETS			
Cash and cash equivalents	3	**873,407**	820,822
Inventories	4	**-**	15,060
Other current assets	5	**8,750**	-
TOTAL CURRENT ASSETS		**882,157**	835,882
TOTAL ASSETS		**882,157**	835,882
LIABILITIES			
CURRENT LIABILITIES			
Accounts payable and other payables	6	**205,585**	34,572
Employee provisions	7	**6,510**	4,590
TOTAL CURRENT LIABILITIES		**212,095**	39,162
TOTAL LIABILITIES		**212,095**	39,162
NET ASSETS		**670,062**	796,720
EQUITY			
Retained surplus		**670,062**	796,720
TOTAL EQUITY		**670,062**	796,720

The accompanying notes form part of these financial statements.

FINANCIAL STATEMENTS 2017/18

FOR THE YEAR ENDED 30 JUNE 2018

Statement of Profit or Loss and Other Comprehensive Income
For the year ended 30 June 2018

	Note	Retained Surplus $	Total $
Balance at 1 July 2016		**229,922**	229,922
Comprehensive Income			
Surplus for the year attributable to members of the entity		**570,769**	570,769
Adjustment to opening retained earnings		**(3,971)**	(3,971)
Total other comprehensive income		**(3,971)**	(3,971)
Total comprehensive income attributable to members of the entity		**566,798**	566,798
Balance at 30 June 2017		**796,720**	796,720
Balance at 1 July 2017		**796,720**	796,720
Comprehensive Income			
Surplus/ (deficit) for the year attributable to members of the entity		**(150,058)**	(150,058)
Adjustment to opening retained earnings		**23,400**	23,400
Total other comprehensive income		**23,400**	23,400
Total comprehensive income attributable to members of the entity		**(126,658)**	(126,658)
Balance at 30 June 2018		**670,062**	670,062

The accompanying notes form part of these financial statements.

Statement of Financial Position
As at 30 June 2018

	Note	2018 $	2017 $
CASH FLOWS FROM OPERATING ACTIVITIES			
Receipts from donations, bequests and grants		**876,617**	1,133,081
Payments to suppliers, employees and grantees		**(841,002)**	(531,974)
Interest received		**18,760**	5,238
Interest paid		**(1,790)**	(2,002)
Net cash generated from operating activities	9	**52,585**	604,343
Net increase in cash held		**52,585**	604,343
Cash on hand at beginning of the financial year		**820,822**	216,479
Cash on hand at end of the financial year	3	**873,407**	820,822

The accompanying notes form part of these financial statements.

FINANCIAL REPORT

FOR THE YEAR ENDED 30 JUNE 2018

NOTE 1 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

The directors have prepared the financial statements on the basis that the company is a non-reporting entity because there are no users dependent on general purpose financial statements. These financial statements are therefore special purpose financial statements that have been prepared in order to meet the requirements of the Corporations Act 2001. The company is a not-for-profit entity for financial reporting purposes under Australian Accounting Standards.

The financial statements have been prepared in accordance with the mandatory Australian Accounting Standards applicable to entities reporting under the Corporations Act 2001 and the significant accounting policies disclosed below, which the directors have determined are appropriate to meet the needs of members. Such accounting policies are consistent with those of previous periods unless stated otherwise.

The financial statements, except for the cash flow information, have been prepared on an accrual basis and are based on historical costs unless otherwise stated in the notes. Material accounting policies adopted in the preparation of these financial statements are presented below and have been consistently applied unless stated otherwise. The amounts presented in the financial statements have been rounded to the nearest dollar.

BASIS OF PREPARATION

Cure4CF Foundation Limited applies Australian Accounting Standards - Reduced Disclosure Requirements as set out in AASB 1053: Application of Tiers of Australian Accounting Standards.

The financial statements are general purpose financial statements that have been prepared in accordance with Australian Accounting Standards - Reduced Disclosure Requirements of the Australian Accounting Standards Board (AASB) and the Australian Charities and Not-for-profits Commission Act 2012. The company is a not-for-profit entity for financial reporting purposes under Australian Accounting Standards.

Australian Accounting Standards set out accounting policies that the AASB has concluded would result in financial statements containing relevant and reliable information about transactions, events and conditions. Material accounting policies adopted in the preparation of these financial statements are presented below and have been consistently applied unless otherwise stated.

The financial statements, except for the cash flow information, have been prepared on an accrual basis and are based on historical costs, modified, where applicable, by the measurement at fair value of selected non-current assets, financial assets and financial liabilities. The amounts presented in the financial statements have been rounded to the nearest dollar.

The financial statements were authorised for issue on Wednesday September 12th by the directors of the company.

ACCOUNTING POLICIES

(A) REVENUE

Non-reciprocal grant revenue is recognised in profit or loss when the entity obtains control of the grant and it is probable that the economic benefits gained from the grant will flow to the entity and the amount of the grant can be measured reliably.

If conditions are attached to the grant which must be satisfied before it is eligible to receive the contribution, the recognition of the grant as revenue will be deferred until those conditions are satisfied.

When grant revenue is received whereby the entity incurs an obligation to deliver economic value directly back to the contributor, this is considered a reciprocal transaction and the grant revenue is recognised in the statement of financial position as a liability until the service has been delivered to the contributor, otherwise the grant is recognised as income on receipt.

Cure4CF Foundation Limited receives non-reciprocal contributions for zero or a nominal value. These assets are recognised at fair value on the date of acquisition in the statement of financial position, with a corresponding amount of income recognised in profit or loss.

Donations and bequests are recognised as revenue when received.

Interest revenue is recognised using the effective interest method, which for floating rate financial assets is the rate inherent in the instrument. Dividend revenue is recognised when the right to receive a dividend has been established.

Revenue from the rendering of a service is recognised upon the delivery of the service to the customers. All revenue is stated net of the amount of goods and services tax.

(B) INVENTORIES

Inventories held for sale are measured at the lower of cost and net realisable value. Inventories held for distribution are measured at cost adjusted, when applicable, for any loss of service potential.

Inventories acquired at no cost, or for nominal consideration, are valued at the current replacement cost as at the date of acquisition.

FINANCIAL REPORT

FOR THE YEAR ENDED 30 JUNE 2018

(C) LEASES

Leases of fixed assets, where substantially all the risks and benefits incidental to the ownership of the asset (but not the legal ownership) are transferred to the entity, are classified as finance leases.

Finance leases are capitalised, recognising an asset and a liability equal to the present value of the minimum lease payments, including any guaranteed residual values.

Leased assets are depreciated on a straight-line basis over their estimated useful lives where it is likely that the entity will obtain ownership of the asset. Lease payments are allocated between the reduction of the lease liability and the lease interest expense for the period.

Lease payments for operating leases, where substantially all the risks and benefits remain with the lessor, are recognised as expenses on a straight-line basis over the lease term.

Lease incentives under operating leases are recognised as a liability and amortised on a straight-line basis over the life of the lease term.

(D) FINANCIAL INSTRUMENTS

Initial Recognition and Measurement

Financial assets and financial liabilities are recognised when the entity becomes a party to the contractual provisions to the instrument. For financial assets, this is equivalent to the date that the company commits itself to either purchase or sell the asset (i.e. trade date accounting is adopted).

Financial instruments are initially measured at fair value plus transactions costs except where the instrument is classified 'at fair value through profit or loss' in which case transaction costs are recognised immediately as expenses in profit or loss.

Classification and Subsequent Measurement

Financial instruments are subsequently measured at fair value (refer to Note 1(q)), amortised cost using the effective interest method, or cost.

Amortised cost is calculated as the amount at which the financial asset or financial liability is measured at initial recognition less principal repayments and any reduction for impairment , and adjusted for any cumulative amortisation of the difference between that initial amount and the maturity amount calculated using the effective interest method.

The effective interest method is used to allocate interest income or interest expense over the relevant period and is equivalent to the rate that exactly discounts estimated future cash payments or receipts (including fees, transaction costs and other premiums or discounts) through the expected life (or when this cannot be reliably predicted, the contractual term) of the financial instrument to the net carrying amount of the financial asset or financial liability. Revisions to expected future net cash flows will necessitate an adjustment to the carrying amount with a consequential recognition of an income or expense item in profit or loss.

(i) Financial assets at fair value through profit or loss

Financial assets are classified at "fair value through profit or loss" when they are held for trading for the purpose of short-term profit taking, derivatives not held for hedging purposes, or when they are designated as such to avoid an accounting mismatch or to enable performance evaluation where a group of financial assets is managed by key management personnel on a fair value basis in accordance with a documented risk management or investment strategy. Such assets are subsequently measured at fair value with changes in carrying amount being included in profit or loss.

(ii) Loans and receivables

Loans and receivables are non-derivative financial assets with fixed or determinable payments that are not quoted in an active market and are subsequently measured at amortised cost. Gains or losses are recognised in profit or loss through the amortisation process and when the financial asset is derecognised.

(iii) Held-to-maturity investments

Held-to-maturity investments are non-derivative financial assets that have fixed maturities and fixed or determinable payments, and it is the company's intention to hold these investments to maturity. They are subsequently measured at amortised cost. Gains or losses are recognised in profit or loss through the amortisation process and when the financial asset is derecognised .

(iv) Available-for-sale investments

Available-for-sale investments are non-derivative financial assets that are either not capable of being classified into other categories of financial assets due to their nature or they are designated as such by management. They comprise investments in the equity of other entities where there is neither a fixed maturity nor fixed or determinable payments.

They are subsequently measured at fair value with any remeasurements other than impairment losses and foreign exchange gains and losses recognised in other comprehensive income. When the financial asset is derecognised, the cumulative gain or loss pertaining to that asset previously recognised in other comprehensive income is reclassified into profit or loss.

Available-for-sale financial assets are classified as non-current assets when they are expected to be sold within 12 months after the end of the reporting period. All other available-for-sale financial assets are classified as current assets.

(v) Financial liabilities

Non-derivative financial liabilities other than financial guarantees are subsequently measured at amortised cost. Gains or losses are recognised in profit or loss through the amortisation process and when the financial liability is derecognised.

Impairment

At the end of each reporting period, the company assesses whether there is objective evidence that a financial asset has been impaired. A financial asset (or a group of financial assets) is deemed to be impaired if, and only if, there is objective evidence of impairment as a result of one or more events (a "loss event") having occurred, which has an impact on the estimated future cash flows of the financial asset(s).

In the case of available-for-sale financial assets, a significant or prolonged decline in the market value of the instrument is considered to constitute a loss event. Impairment losses are recognised in profit or loss immediately. Also, any cumulative decline in fair value previously recognised in other comprehensive income is reclassified to profit or loss at this point.

In the case of financial assets carried at amortised cost, loss events may include: indications that the debtors or a group of debtors are experiencing significant financial difficulty, default or delinquency in interest or principal payments; indications that they will enter bankruptcy or other financial reorganisation; and changes in arrears or economic conditions that correlate with defaults.

For financial assets carried at amortised cost (including loans and receivables), a separate allowance account is used to reduce the carrying amount of financial assets impaired by credit losses. After having taken all possible measures of recovery, if management establishes that the carrying amount cannot be recovered by any means, at that point the written-off amounts are charged to the allowance account or the carrying amount of impaired financial assets is reduced directly if no impairment amount was previously recognised in the allowance accounts.

When the terms of financial assets that would otherwise have been past due or impaired have been renegotiated, the company recognises the impairment for such financial assets by taking into account the original terms as if the terms have not been renegotiated so that the loss events that have occurred are duly considered.

Derecognition

Financial assets are derecognised where the contractual rights to receipt of cash flows expire or the asset is transferred to another party whereby the entity no longer has any significant continuing involvement in the risks and benefits associated with the asset. Financial liabilities are derecognised when the related obligations are discharged, cancelled or have expired. The difference between the carrying amount of the financial liability, which is extinguished or transferred to another party, and the fair value of consideration paid, including the transfer of non-cash assets or liabilities assumed, is recognised in profit or loss.

(E) IMPAIRMENT OF ASSETS

At the end of each reporting period, the entity assesses whether there is any indication that an asset may be impaired. If such an indication exists, an impairment test is carried out on the asset by comparing the recoverable amount of the asset, being the higher of the asset's fair value less costs of disposal and value in use, to the asset's carrying amount. Any excess of the asset's carrying amount over its recoverable amount is recognised immediately in profit or loss, unless the asset is carried at a revalued amount in accordance with another Standard (e.g. in accordance with the revaluation model in AASB 116). Any impairment loss of a revalued asset is treated as a revaluation decrease in accordance with that other Standard.

Where it is not possible to estimate the recoverable amount of an individual asset, the entity estimates the recoverable amount of the cash-generating unit to which the asset belongs.

Impairment testing is performed annually for goodwill and intangible assets with indefinite lives

(F) EMPLOYEE BENEFITS

Short-term employee benefits

Provision is made for the Company's obligation for short-term employee benefits . Short-term employee benefits are benefits (other than termination benefits) that are expected to be settled wholly within 12 months after the end of the annual reporting period in which the employees render the related service, including wages, salaries and sick leave. Short-term employee benefits are measured at the (undiscounted) amounts expected to be paid when the obligation is settled.

The company's obligations for short-term employee benefits such as wages, salaries and sick leave are recognised as part of current trade and other payables in the statement of financial position.

Other long-term employee benefits

The company classifies employees' long service leave and annual leave entitlements as other long-term employee benefits as they are not expected to be settled wholly within 12 months after the end of the annual reporting period in which the employees render the related service. Provision is made for the company's obligation for other long-term employee benefits, which are measured at the present value of the expected future payments to be made to employees. Expected future payments incorporate anticipated future wage and salary levels, durations of service and employee departures, and are discounted at rates determined by reference to market yields at the end of the reporting period on government bonds that have maturity dates that approximate the terms of the obligations. Upon the remeasurement of obligations for other long-term employee benefits, the net change in the obligation is recognised in profit or loss classified under employee benefits expense.

FINANCIAL REPORT

FOR THE YEAR ENDED 30 JUNE 2018

The Company's obligations for long-term employee benefits are presented as non-current liabilities in its statement of financial position, except where the Company does not have an unconditional right to defer settlement for at least twelve months after the reporting date, in which case the obligations are presented as current liabilities.

(G) CASH AND CASH EQUIVALENTS

Cash and cash equivalents include cash on hand, deposits held at-call with banks, other short-term highly liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within short-term borrowings in current liabilities on the statement of financial position.

(H) GOODS AND SERVICES TAX (GST)

Revenues, expenses and assets are recognised net of the amount of GST, except where the amount of GST incurred is not recoverable from the Australian Taxation Office (ATO).

Receivables and payables are stated inclusive of the amount of GST receivable or payable. The net amount of GST recoverable from, or payable to, the ATO is included with other receivables or payables in the statement offinancial position.

Cash flows are presented on a gross basis. The GST components of cash flows arising from investing or financing activities which are recoverable from, or payable to, the ATO are presented as operating cash flows included in receipts from customers or payments to suppliers.

(I) INCOME TAX

No provision for income tax has been raised as the entity is exempt from income tax under Div 50 of the Income Tax Assessment Act 1997.

U) PROVISIONS

Provisions are recognised when the entity has a legal or constructive obligation, as a result of past events, for which it is probable that an outflow of economic benefits will result and that outflow can be reliably measured. Provisions recognised represent the best estimate of the amounts required to settle the obligation at the end of reporting period.

(K) COMPARATIVE FIGURES

When required by Accounting Standards comparative figures have been adjusted to conform to changes in presentation for the current financial year.

(I) TRADE AND OTHER PAYABLES

Trade and other payables represent the liabilities for goods and services received by the company during the reporting period that remain unpaid at the end of the reporting period. The balance is recognised as a current liability with the amounts normally paid within 30 days of recognition of the liability.

(M) CRITICAL ACCOUNTING ESTIMATES AND JUDGEMENTS

The directors evaluate estimates and judgements incorporated into the financial statements based on historical knowledge and best available current information. Estimates assume a reasonable expectation of future events and are based on current trends and economic data, obtained both externally and within the company.

There are no critical accounting estimates or judgements required.

(N) FAIR VALUE OF ASSETS AND LIABILITIES

The company measures some of its assets and liabilities at fair value on either a recurring or non-recurring basis, depending on the requirements of the applicable Accounting Standard.

"Fair value" is the price the company would receive to sell an asset or would have to pay to transfer a liability in an orderly (ie unforced) transaction between independent, knowledgeable and willing market participants at the measurement date.

As fair value is a market-based measure, the closest equivalent observable market pricing information is used to determine fair value. Adjustments to market values may be made having regard to the characteristics of the specific asset or liability. The fair values of assets and liabilities that are not traded in an active market are determined using one or more valuation techniques. These valuation techniques maximise, to the extent possible, the use of observable market data.

To the extent possible, market information is extracted from the principal market for the asset or liability (ie the market with the greatest volume and level of activity for the asset or liability). In the absence of such a market, market information is extracted from the most advantageous market available to the entity at the end of the reporting period (ie the market that maximises the receipts from the sale of the asset or minimises the payments made to transfer the liability, after taking into account transaction costs and transport costs).

For non-financial assets, the fair value measurement also takes into account a market participant's ability to use the asset in its highest and best use or to sell it to another market participant that would use the asset in its highest and best use.

FINANCIAL REPORT

FOR THE YEAR ENDED 30 JUNE 2018

The fair value of liabilities and the entity's own equity instruments (if any) may be valued, where there is no observable market price in relation to the transfer of such financial instrument, by reference to observable market information where such instruments are held as assets. Where this information is not available, other valuation techniques are adopted and where significant, are detailed in the respective note to the financial statements.

(O) NEW AND AMENDED ACCOUNTING STANDARDS

The entity has assessed all new and amended accounting standards issued and effective for financial reporting periods beginning on or after 1 January 2017, and determined there to be no effect on the current or prior period financial statements.

NOTE 2 REVENUE AND OTHER INCOME

	2018	2017
Revenue	**$**	**$**
Revenue from continuing operations		
Ambassadors circle	**65,000**	69,500
Community fundraising	**140,408**	96,048
Community reward accounts	**-**	2,189
Corporate donations	**17,000**	7,556
Everyday hero	**-**	72,053
Fundraising events	**-**	13,812
General donations	**8,693**	14,913
Learning for impact grant income	**20,073**	69,927
Major gifts	**200,000**	170,000
Personal campaigns	**40,500**	-
Regular giving income	**2,732**	36
The circle income	**4,200**	4,200
Trusts and foundations	**334,431**	566,238
Wine sales	**3,394**	1,711
Other	**8,927**	-
Total revenue	**845,358**	1,088,183
Other income		
- Interest income	**15,366**	5,520
Total other income	**15,366**	5,520
Total revenue and other income	**860,724**	1,093,703

FINANCIAL REPORT

FOR THE YEAR ENDED 30 JUNE 2018

NOTE 3 CASH AND CASH EQUIVALENTS

	2018	2017
CURRENT	**$**	**$**
Cash at bank	**873,407**	820,822
Cash on hand	**873,407**	820,822
	873,407	820,822

NOTE 4 INVENTORIES

	2018	2017
CURRENT	**$**	**$**
At cost:	**-**	15,060
Inventory	**-**	15,060

NOTE 5 OTHER ASSETS

	2018	2017
	$	**$**
Prepayments	**8,750**	-
	8,750	-

NOTE 6 TRADE AND OTHER PAYABLES

	Note	2018	2017
		$	**$**
CURRENT			
Accounts payable		**28,570**	26,000
Deferred income		**166,798**	20,073
Other current payables		**9,638**	9,463
GST payable		**579**	(20,964)
	6(a)	**205,585**	34,572
(a) Financial liabilities at amortised cost classified as accounts payable and other payables Accounts payable and other payables:			
- Total current		**205,585**	34,572
		205,585	34,572
Less deferred income		**(166,798)**	(20,073)
Less other payables (net amount of GST payable)		**(9,638)**	(9,463)
Financial liabilities as accounts payable and other payables	10	**29,149**	5,036

FINANCIAL REPORT

FOR THE YEAR ENDED 30 JUNE 2018

NOTE 7 PROVISIONS

	2018	2017
CURRENT	**$**	**$**
Provision for employee benefits: annual leave	**6,510**	4,590
Provision for employee benefits: long service leave		
	6,510	4,590
NON-CURRENT		
Provision for employee benefits: long service leave		
	6,510	4,590

EMPLOYEE PROVISIONS

Employee provisions represents amounts accrued for annual leave and long service leave.

The current portion for this provision includes the total amount accrued for annual leave entitlements and the amounts accrued for long service leave entitlements that have vested due to employees having completed the required period of service. Based on past experience, the company does not expect the full amount of annual leave or long service leave balances classified as current liabilities to be settled within the next 12 months. However, these amounts must be classified as current liabilities since the company does not have an unconditional right to defer the settlement of these amounts in the event employees wish to use their leave entitlement.

The non-current portion for this provision includes amounts accrued for long service leave entitlements that have not yet vested in relation to those employees who have not yet completed the required period of service.

In calculating the present value of future cash flows in respect of long service leave, the probability of long service leave being taken is based upon historical data. The measurement and recognition criteria for employee benefits have been discussed in Note 1(g).

NOTE 8 EVENTS AFTER THE REPORTING PERIOD

The directors are not aware of any significant events since the end of the reporting period.

NOTE 9 CASH FLOW INFORMATION

	2018	2017
Reconciliation of Cash Flows from Operating Activities with	**$**	**$**
Net Current Year Surplus		
Net current year surplus	**(150,058)**	570,769
Adjustment for:		
Retained earnings adjustment	**23,400**	(3,971)
Movement in working capital changes:		
(Increase)/decrease in accounts receivable and other debtors	**21,543**	(11,092)
Increase/(decrease) in accounts payable and other payables	**149,470**	26,832
Increase/(decrease) in employee provisions	**1,920**	4,590
(Increase)/decrease in inventories on hand	**15,060**	17,215
(Increase)/decrease in prepayments	**(8,750)**	-
	52,585	604,343

FINANCIAL REPORT

FOR THE YEAR ENDED 30 JUNE 2018

NOTE 10 FINANCIAL RISK MANAGEMENT

The company's financial instruments consist mainly of deposits with banks, local money market instruments, short-term and long-term investments, receivables and payables, and lease liabilities.

The carrying amounts for each category of financial instruments, measured in accordance with AASB 139 as detailed in the accounting policies to these financial statements, are as follows:

		2018	2017
Financial assets	Note	**$**	$
Cash and cash equivalents	3	**873,407**	820,822
Total financial assets		**873,407**	820,822
Financial liabilities			
Financial liabilities at amortised cost:			
- accounts payable and other payables	6(a)	**29,149**	5,036
Total financial liabilities		**29,149**	5,036

NOTE 11 KEY MANAGEMENT PERSONNEL COMPENSATION

Key Management Personnel

Any person(s) having authority and responsibility for planning, directing and controlling the activities of the entity directly or indirectly, including any director (whether executive or otherwise) is considered key management personnel (KMP). The Executive Manager along with Directors are considered key management personnel. Directors receive nil remuneration.

The totals of remuneration paid to KMP of the company during the year are as follows:

	2018	2017
KMP compensation:	**$**	$
short-term employee benefits	**82,548**	37,879
post-employment benefits	**7,451**	3,598
other long-term benefits		
	89,999	41,477

NOTE 12 RELATED PARTY TRANSACTIONS

The Company's related parties include its key management personnel and related entities. Unless otherwise stated, none of the transactions incorporate special terms and conditions and no guarantees were given or received.

Board director Jo Close is the founder and principal of research consulting firm Research Innovations. The Board approved the engagement of Research Innovations to deliver the facilitation and drafting of a five-year operational plan for the Cystic Fibrosis Airway Research Group as well as continued reporting and monitoring of progress against the plan. The amounts billed within the year ended 30 June 2017 were based on normal market rates and amounted to $4,482.70. There were no related party transactions within the year ended 30 June 2018.

NOTE 13 ENTITY DETAILS

The registered office of the entity is: Cure4CF Foundation Limited PO Box 313 Greenwith SA 5125

The principal place of business is: Cure4CF Foundation Limited PO Box 313 Greenwith SA 5125

NOTE 14 MEMBERS' GUARANTEE

The entity is incorporated under the Corporations Act 2001 and is a company limited by guarantee . If the entity is wound up, the constitution states that each member is required to contribute a maximum of $1O towards meeting any outstanding obligations of the entity. At 30 June 2018 the number of members was 10.

FINANCIAL REPORT

FOR THE YEAR ENDED 30 JUNE 2018

DIRECTORS' DECLARATION

In accordance with a resolution of the directors of Cure4CF Foundation Limited , the directors declare that:

1. The financial statements and notes, as set out on pages 4 to 15, are in accordance with the Australian Charities and Not-for-profits Commission Act 2012 and:

(a) comply with Australian Accounting Standards - Reduced Disclosure Requirements ; and

(b) give a true and fair view of the financial position of the registered entity as at 30 June 2018 and of its performance for the year ended on that date.

2. There are reasonable grounds to believe that the registered entity will be able to pay its debts as and when they become due and payable.

This declaration is signed in accordance with subs 60.15(2) of the Australian Charities and Not-for-profits Commission Regulation 2013.

Director 

David Coluccio

Dated this Wednesday12th day of September 2018

FINANCIAL REPORT

AUDITOR'S RESPONSIBILITIES FOR THE AUDIT OF THE FINANCIAL REPORT

INDEPENDENT AUDITOR'S REPORT

To the Members of Cure4CF Foundation Limited

Qualified Opinion

We have audited the financial report of Cure4CF Foundation Limited, which comprises the statement of financial position as at 30 June 2018, the statement of comprehensive income, statement of changes in equity and statement of cash flows for the year then ended, and notes to the financial statements, including a summary of significant accounting policies, and the responsible entities' declaration.

In our opinion, except for the effects of the matter described in the Basis for Qualified Opinion section of our report, the accompanying financial report of Cure4CF Foundation Limited has been prepared in accordance with Division 60 of the Australian Charities and Not-for-Profits Commission Act 2012 (the ACNC Act), including:

(a) giving a true and fair view of the registered entity's financial position as at 30 June 2018 and of its financial performance for the year then ended; and
(b) complying with Australian Accounting Standards to the extent described in Note 1, and Division 60 the Australian Charities and Not-for-profits Commission Regulation 2013.

BASIS FOR QUALIFIED OPINION

The Cure4CF Foundation Limited has determined that it is impracticable to establish control over the collection of cash donations prior to entry into its financial records. Accordingly, as the evidence available to us regarding fundraising revenue from this source was limited, our audit procedures with respect to cash donations had to be restricted to the amounts recorded in the financial records. We therefore are unable to express an opinion on whether the recorded cash donations of Cure4CF Foundation Limited are complete.

We conducted our audit in accordance with Australian Auditing Standards. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Report section of our report. We are independent of the registered entity in accordance with the auditor independence requirements of the ACNC Act and ethical requirements of the Accounting Professional and Ethical Standards Board's APES 110 Code of Ethics for Professional Accountants (the Code) that are relevant to our audit of the financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

EMPHASIS OF MATTER - BASIS OF ACCOUNTING

We draw attention to Note 1 to the financial report, which describes the basis of accounting. The financial report has been prepared for the purpose of fulfilling the registered entity's financial reporting responsibilities under the ACNC Act. As a result, the financial report may not be suitable for another purpose. Our opinion is not modified in respect of this matter.

RESPONSIBILITY OF THE DIRECTORS FOR THE FINANCIAL REPORT

The directors of the registered entity are responsible for the preparation of the financial report that gives a true and fair view and have determined that the basis of preparation described in Note 1 to the financial report is appropriate to meet the requirements of the ACNC Act and the needs of the members. The directors' responsibility also includes such internal control as the responsible entities determine is necessary to enable the preparation of a financial report that gives a true and fair view and is free from material misstatement, whether due to fraud or error.

In preparing the financial report, the directors are responsible for assessing the registered entity's ability to continue as a going concern, disclosing, as applicable, matters relating to going concern and using the going concern basis of accounting unless the responsible entities either intend to liquidate the registered entity or to cease operations, or have no realistic alternative but to do so.

sjn Chartered Accountants
ABN 29 191 937 410
1 Alexandra Avenue
Rose Park, SA 5067
PO Box 410
Glenside, SA 5065
P: 08 8333 7300
F: 08 8333 7301
info@sjnca.com.au
www.sjnca.com.au

FINANCIAL REPORT

AUDITOR'S RESPONSIBILITIES FOR THE AUDIT OF THE FINANCIAL REPORT

Our objectives are to obtain reasonable assurance about whether the financial report as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with the Australian Auditing Standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the financial report.

As part of an audit in accordance with Australian Auditing Standards, we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial report, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the registered entity's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by responsible entities.
- Conclude on the appropriateness of responsible entities' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the registered entity's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial report or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the registered entity to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial report, including the disclosures, and whether the financial report represents the underlying transactions and events in a manner that achieves fair presentation.

We communicate with the directors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

SJN Chartered Accountants

Adam Drabsch
Director
Adelaide
12th September 2018

sjn Chartered Accountants
ABN 29 191 937 410
1 Alexandra Avenue
Rose Park, SA 5067
PO Box 410
Glenside, SA 5065
P: 08 8333 7300
F: 08 8333 7301
info@sjnca.com.au
www.sjnca.com.au